柳藥股份(603368.SH):8.02億元可轉債24日起上市
格隆匯2月19日丨柳藥股份(603368.SH)公佈,公司於2020年1月16日公開發行了802.20萬張可轉換公司債券,每張面值100元,發行總額8.022億元。本次發行向原股東優先配售,原股東優先配售後餘額部分(含原股東放棄優先配售部分)採用網上通過上交所交易系統向社會公眾投資者發售的方式進行,認購金額不足8.022億元的部分由保薦機構(主承銷商)包銷。
經上海證券交易所自律監管決定書[2020]53號同意,公司發行的8.022億元可轉換公司債券於2020年2月24日起在上海證券交易所上市交易,債券簡稱為“柳藥轉債”,債券代碼為“113563”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.